前癃通胶囊治疗良性前列腺增生症120例

前癃通胶囊是我省著名男性病专家贺菊乔教授治疗良性前列腺增生症(BPH)的经验方,在我院已应用20余年,临床疗效显著。为进一步评估该药治疗BPH的疗效和安全性,我们从2013年2月~2014年3月对120例BPH患者进行系统观察,并采用前癃通胶囊和癃闭舒胶囊作对照治疗。对比观察两组国际前列腺症状(I-PSS)评分、尿流率、残余尿量等,对前癃通胶囊的疗效作出客观评价,现总结报道如下。     

前癃通胶囊对气虚血瘀型良性前列腺增生尿动力学的影响

目的:观察前癃通胶囊对气虚血瘀型良性前列腺增生尿动力学的影响.方法:将60例患者随机分成治疗组和对照组,分别给予前癃通胶囊和癃闭舒胶囊治疗,观察I-PSS评分、尿流率、前列腺体积、残余尿量等.结果:治疗组疗效优于对照组(P＜0.05),各项指标改善亦优于对照组(P＜0.05).结论:前癃通胶囊是治疗良性前列腺增生的有效药物.     

1083例慢性前列腺炎中医证型分布调查研究

目的 探讨慢性非细菌性前列腺炎的中医证型分布、病机特点及演变规律.方法 随机调查湖南中医药大学第一附属医院中医外科门诊的慢性前列腺炎患者1 083例,了解慢性前列腺炎的中医证型分布、兼证特点,中医证侯与西医诊断分型、病程、年龄的关系.结果 1 083例慢性前列腺炎患者以CAP/CPPS(Ⅲ型)多见,占总数的91.2%.中医证型分布调查结果显示,湿热蕴阻、气滞血瘀两证的比例为91.51%与84.30%;出现单一证的比例小,为3.88%与2.22%.临床大多表现为兼夹证,以湿热蕴阻+气滞血瘀证最多,达56.79%,其次为湿热蕴阻+气滞血疼+肾阳不足证,为14.59%,两类证占所有证型70%以上;单一湿热蕴阻证多出现在病程小于6个月的患者中,病程大于6个月以上患者则出现极少;随病程延长,出现肾虚兼证比例增多.在年龄结构分布中,30岁以下出现肾虚兼证少,30岁以上者出现肾虚兼证多.结论 慢性前列腺炎的基本病机为湿热抉瘀,湿热挟瘀证是其临床曩常见中医证型.     

凉血解毒汤治疗结节性红斑37例小结

结节性红斑为常见于下肢的皮肤结节性疾病,其临床特征为复发性、疼痛的结节,病理呈慢性良性经过,全身症状不明显,发病机制尚不清楚[1].笔者自拟凉血解毒汤治疗结节性红斑37例,效果显著,现总结如下.     

慢性非细菌性前列腺炎/慢性盆腔疼痛综合征患者前列腺液中炎症因子差异表达的临床意义

Objective To investigate the role of inflammatory cytokines in the pathogenesis of chronic non-bacterial prostatitis/chronic pelvic pain syndrome (CAP/CPPS) patients. Methods The 38 cases with CAP/CPPS patients (18 cases of CAP and 20 cases of CPPS) and 20 cases of healthy controls were selected. The differential expressions of 40 kinds of inflammatory cytokines were detec-ted by antibody arrays in prostate fluid. Results The inflammatory cytokines which increased more than 1.5 times expression have been found. There were seven kinds in CAP including monocyte che-moattractant protein (MCP)-1, solution tumor necrosis factor receptor Ⅱ(s TNF R Ⅱ), platelet-de-rived growth faetor-BB (PDGF-BB), interleukin (IL)-β, IL-11、IL-6、MCP-2 and five kinds in CPPS groups including MCP-1、PDGF-BB、MCP-2、s TNF R Ⅱ、It-11 respectively, compared with healthy control group. The cluster analysis results showed that protein expression of Monocyte chemoattrac-tant protein 1 (MCP-1)and platelet-derived growth factor BB (PDGF-BB) were significantly increased in CAP (3.47 and 2.07 times) and CPPS (2.25 and 2.19 times) compared with healthy control group and were the final polymerization of inflammatory cytokines. The protein expression of interleukin 1 β (IL-1 β), MCP-1 and soluble tumor necrosis factor Ⅱ (s TNF R Ⅱ) in CAP group was increased more than 1.85,1.55,1.67 times compared with CPPS group. Conclusions Elevated expression of inflammatory cytokines may play an important role in the course of CAP/CPPS disease. The extent of the inflammatory response of CAP was higher than CPPS. The inflammatory factors of MCP-1 and PDGF-BB could serve as a novel diagnostic marker.     

慢性非细菌性前列腺炎/慢性盆腔疼痛综合征患者前列腺液中炎症因子差异表达的临床意义

Objective To investigate the role of inflammatory cytokines in the pathogenesis of chronic non-bacterial prostatitis/chronic pelvic pain syndrome (CAP/CPPS) patients. Methods The 38 cases with CAP/CPPS patients (18 cases of CAP and 20 cases of CPPS) and 20 cases of healthy controls were selected. The differential expressions of 40 kinds of inflammatory cytokines were detec-ted by antibody arrays in prostate fluid. Results The inflammatory cytokines which increased more than 1.5 times expression have been found. There were seven kinds in CAP including monocyte che-moattractant protein (MCP)-1, solution tumor necrosis factor receptor Ⅱ(s TNF R Ⅱ), platelet-de-rived growth faetor-BB (PDGF-BB), interleukin (IL)-β, IL-11、IL-6、MCP-2 and five kinds in CPPS groups including MCP-1、PDGF-BB、MCP-2、s TNF R Ⅱ、It-11 respectively, compared with healthy control group. The cluster analysis results showed that protein expression of Monocyte chemoattrac-tant protein 1 (MCP-1)and platelet-derived growth factor BB (PDGF-BB) were significantly increased in CAP (3.47 and 2.07 times) and CPPS (2.25 and 2.19 times) compared with healthy control group and were the final polymerization of inflammatory cytokines. The protein expression of interleukin 1 β (IL-1 β), MCP-1 and soluble tumor necrosis factor Ⅱ (s TNF R Ⅱ) in CAP group was increased more than 1.85,1.55,1.67 times compared with CPPS group. Conclusions Elevated expression of inflammatory cytokines may play an important role in the course of CAP/CPPS disease. The extent of the inflammatory response of CAP was higher than CPPS. The inflammatory factors of MCP-1 and PDGF-BB could serve as a novel diagnostic marker.     

前癃通胶囊治疗良性前列腺增生症的临床观察

目的观察前癃通胶囊治疗良性前列腺增生症（BPH）的临床疗效。方法将80例BPH患者随机分为治疗组和对照组,分别给予前癃通胶囊和癃闭舒胶囊治疗,1个月为1个疗程,连续治疗3个疗程。观察治疗前后I-PSS评分、尿流率、前列腺体积、残余尿量等的变化。结果治疗组总疗效优于对照组,差异具有统计学意义（P〈0.05）;各项指标改善亦优于对照组,差异具有统计学意义（P〈0.05）。结论前癃通胶囊是治疗良性前列腺增生症的有效药物,值得临床推荐使用。     

乳痛软坚片治疗痰瘀互结型乳腺增生病30例临床观察

目的:观察乳痛软坚片治疗痰瘀互结型乳腺增生病的疗效。方法:将60例中医辨证为痰瘀互结的乳腺增生病患者随机分为治疗组和对照组各30例。对照组采用红金消结胶囊治疗;治疗组用乳痛软坚片治疗。两组均经期停药,1月为1个疗程,治疗3个疗程后观察比较两组肿块大小评分、中医症候总积分及综合疗效。结果:两组均可明显缩小肿块、降低中医症候积分。两组比较,治疗组作用更显著(P<0.05);两组综合疗效比较差异有统计学意义(P<0.05)。结论:乳痛软坚片可以有效地改善痰瘀互结型乳腺增生病患者的症状及体征,疗效确切。     

从内伤火病论治早泄

文章主要从“火”的不同角度辨析早泄的病因病机和证治。基于早泄的病因病机特点,从“阴火”“君相之火”“五志过极皆可为火”“痰火”四个方面来阐述早泄的发病机理。内伤脾胃,气虚不运,升降不济,阴火内生,精关不固;三焦郁滞,阴火内生;君火以明,相火以位,君相二火失和,则致宗筋功能失常,失去正常的启用功能;情志不舒,五志过极化火而精气不固者;肾亏虚火上炎,炼津为痰,扰动精室,精关易开,皆可导致早泄。治疗思路上,升阳散火、引火归元、解郁散火、化痰散火为早泄的主要治法。     

三草安前汤直肠滴注治疗慢性前列腺炎30例临床观察

目的:观察三草安前汤直肠滴注治疗慢性前列腺炎的临床疗效。方法:将60例慢性前列腺炎患者随机分为治疗组和对照组各30例。分别采用三草安前汤直肠滴注和野菊花栓塞肛治疗。3个疗程后观察比较两组综合疗效。结果:总有效率治疗组为86.7%,对照组为73.3%,治疗组优于对照组(P<0.05)。结论:三草安前汤直肠滴注治疗慢性前列腺炎疗效显著。